Literature DB >> 6328747

Transforming proteins of fujinami and PRCII avian sarcoma viruses have different subcellular locations.

J Woolford, K Beemon.   

Abstract

The subcellular locations of transforming proteins encoded by the related avian sarcoma viruses, PRCII and Fujinami sarcoma virus (FSV), were compared by cell fractionation and by indirect immunofluorescence. Whereas both viruses encode gag-fps proteins associated with tyrosine-specific kinase activity, FSV is more highly tumorigenic than PRCII in vivo. Cell fractionation studies showed that the PRCII transforming protein, P105, became associated with the high-speed particulate fraction shortly after synthesis. However, PRCII P105 did not fractionate with the plasma membrane marker, but rather with high-density membranes. It is unique in this subcellular localization among viral tyrosine kinases. This membrane association was found to be relatively insensitive to salt concentration and did not require divalent cations. Immunofluorescent studies, using anti-fps serum, showed that the PRCII protein was present in discrete, large, cytoplasmic patches, as well as in a juxtanuclear location. In contrast, FSV-encoded P130 was found to fractionate with the plasma membrane marker when cells were analyzed in low salt in the presence of magnesium. However, at higher salt concentrations and in the absence of magnesium, the bulk of P130 was found to be soluble. Immunofluorescent staining of FSV P130 revealed a diffuse, cytoplasmic pattern that was distinct from that of the PRCII product. The observed difference in the subcellular localization of these transforming proteins may be the cause of the difference in tumorigenicity between the two viruses.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6328747     DOI: 10.1016/0042-6822(84)90127-2

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  9 in total

1.  Development and characterization of a panel of monoclonal antibodies against the catalytic domain of the human fes proto-oncogene product.

Authors:  A van Bokhoven; H L van Duijnhoven; M Jücker; A J Roebroek; W J van de Ven
Journal:  Mol Biol Rep       Date:  1992-02       Impact factor: 2.316

2.  Localization of the feline sarcoma virus fgr gene product (P70gag-actin-fgr): association with the plasma membrane and detergent-insoluble matrix.

Authors:  R Manger; S Rasheed; L Rohrschneider
Journal:  J Virol       Date:  1986-07       Impact factor: 5.103

3.  The myristylation signal of p60v-src functionally complements the N-terminal fps-specific region of P130gag-fps.

Authors:  A R Brooks-Wilson; E Ball; T Pawson
Journal:  Mol Cell Biol       Date:  1989-05       Impact factor: 4.272

4.  Cellular localization of c-fps gene product NCP98.

Authors:  J C Young; G S Martin
Journal:  J Virol       Date:  1984-12       Impact factor: 5.103

5.  Localization of the v-rel protein in reticuloendotheliosis virus strain T-transformed lymphoid cells.

Authors:  S L Simek; R M Stephens; N R Rice
Journal:  J Virol       Date:  1986-07       Impact factor: 5.103

6.  Cellular localization of the transforming protein of wild-type and temperature-sensitive Fujinami sarcoma virus.

Authors:  P Moss; K Radke; V C Carter; J Young; T Gilmore; G S Martin
Journal:  J Virol       Date:  1984-11       Impact factor: 5.103

7.  Two yeast genes that encode unusual protein kinases.

Authors:  D E Levin; C I Hammond; R O Ralston; J M Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  1987-09       Impact factor: 11.205

8.  Construction and biological analysis of deletion mutants of Fujinami sarcoma virus: 5'-fps sequence has a role in the transforming activity.

Authors:  K Ariizumi; M Shibuya
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

9.  pp60c-src has less affinity for the detergent-insoluble cellular matrix than do pp60v-src and other viral protein-tyrosine kinases.

Authors:  D M Loeb; J Woolford; K Beemon
Journal:  J Virol       Date:  1987-08       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.